Advertisement

mRNA Technology Being Considered By Drug Companies For Flu Shots

While companies including Moderna, Pfizer and Sanofi have just started Phase 1 trials of mRNA-based seasonal flu vaccine candidates, others are expected to follow suit next year.

Following COVID-19's validation of mRNA technology, many pharmaceutical companies are racing to use the same recipe to make influenza vaccines, according to Nature.

While companies including Moderna, Pfizer and Sanofi have just started Phase 1 trials of mRNA-based seasonal flu vaccine candidates, others are expected to follow suit next year.

Unlike COVID-19, however, mRNA-based flu injections may prove to be a more difficult test, given nine flu vaccines from four distinct vaccine manufacturers are already available in the United States.

According to Nature, following Covid-19's validation of mRNA technology, multiple pharmaceutical companies are racing to employ the same recipe to manufacture influenza vaccines.

While Moderna, Pfizer and Sanofi have only recently begun Phase 1 trials of mRNA-based seasonal flu vaccine candidates, others are anticipated to follow suit next year.

mRNA-based flu injections, in contrast to COVID-19, may prove to be a more difficult test, given that nine flu vaccinations from four different vaccine manufacturers are already available in the United States.



Advertisement

Around The World